Neurent Medical has announced the limited commercial availability of its NEUROMARK Rhinitis Neurolysis Therapy (RNT) in the US markets for the treatment of chronic rhinitis.

The market release comes after the American Medical Association (AMA) recently released a new Category I Current Procedural Terminology (CPT) code for posterior nasal nerve ablation (PNN) procedures. The list also includes NEUROMARK.

The code will become operative in January 2024. Additionally, the procedure is supported by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), said Neurent Medical.

The Ireland-based medical device startup has designed the NEUROMARK system to disrupt the parasympathetic nerve signals using controlled low-power radio frequency (RF) energy in the targeted nasal cavity regions.

According to Neurent Medical, disrupting the nerve signal can cause an inflammatory reaction in the targeted nasal regions.

The design and advanced algorithmic control of the NEUROMARK system is said to enable physicians accurately target and safely disrupt many underlying nerve branches in a single procedure to ease chronic rhinitis symptoms and enhance patient quality of life.

This new approach gives ENTs a leaflet design with the intelligence and flexibility to help deliver precision neurolysis of posterior nasal nerves. It is also suitable for a variety of anatomies, the medical device firm claimed.

The venture capital-backed company said that NEUROMARK’s intelligent technology platform enables otolaryngologists to treat chronic rhinitis with precision and improve the patient experience from treatment through recovery.

Neurent Medical CEO Brian Shields said: “Our goal is to provide an easy-to-operate, smart treatment that provides clinicians with more precise control and confidence, and patients with a safe, comfortable experience.

“The new CPT code underscores the value of this technology as we further grow our commercial presence in the U.S. and work to make NEUROMARK more accessible to the millions of patients living with chronic rhinitis today.”